A detailed history of Royal Bank Of Canada transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Royal Bank Of Canada holds 2,855 shares of PRLD stock, worth $3,711. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,855
Previous 2,939 2.86%
Holding current value
$3,711
Previous $11,000 54.55%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.07 - $6.37 $173 - $535
-84 Reduced 2.86%
2,855 $5,000
Q2 2024

Aug 14, 2024

BUY
$3.32 - $5.63 $2,941 - $4,988
886 Added 43.16%
2,939 $11,000
Q1 2024

Nov 05, 2024

SELL
$2.68 - $4.84 $2,374 - $4,288
-886 Reduced 30.15%
2,053 $9,000
Q1 2024

May 15, 2024

SELL
$2.68 - $4.84 $18,725 - $33,817
-6,987 Reduced 77.29%
2,053 $9,000
Q4 2023

Feb 14, 2024

BUY
$1.69 - $4.37 $6,721 - $17,379
3,977 Added 78.55%
9,040 $38,000
Q3 2023

Nov 14, 2023

SELL
$2.74 - $4.79 $591 - $1,034
-216 Reduced 4.09%
5,063 $15,000
Q2 2023

Aug 14, 2023

BUY
$4.45 - $8.12 $93 - $170
21 Added 0.4%
5,279 $23,000
Q1 2023

May 15, 2023

BUY
$4.58 - $7.34 $4,392 - $7,039
959 Added 22.31%
5,258 $29,000
Q4 2022

Feb 14, 2023

BUY
$4.61 - $8.5 $456 - $841
99 Added 2.36%
4,299 $25,000
Q3 2022

Nov 14, 2022

BUY
$5.0 - $8.82 $8,495 - $14,985
1,699 Added 67.93%
4,200 $28,000
Q2 2022

Aug 15, 2022

SELL
$4.0 - $7.55 $2,660 - $5,020
-665 Reduced 21.0%
2,501 $13,000
Q1 2022

May 16, 2022

SELL
$6.9 - $13.22 $11,495 - $22,024
-1,666 Reduced 34.48%
3,166 $22,000
Q4 2021

Feb 14, 2022

SELL
$11.89 - $31.74 $879 - $2,348
-74 Reduced 1.51%
4,832 $61,000
Q3 2021

Nov 15, 2021

BUY
$25.78 - $38.65 $32,225 - $48,312
1,250 Added 34.19%
4,906 $153,000
Q2 2021

Aug 16, 2021

BUY
$28.63 - $44.3 $104,671 - $161,960
3,656 New
3,656 $104,000

Others Institutions Holding PRLD

About Prelude Therapeutics Inc


  • Ticker PRLD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,369,200
  • Market Cap $47.3M
  • Description
  • Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...
More about PRLD
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.